Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS).

Authors

null

Iris Yeong- Fung Sheng

Cleveland Clinic, Cleveland, OH

Iris Yeong- Fung Sheng , C. Marcela Diaz-Montero , Patricia A. Rayman , Wei (Auston) Wei , Jaleh Fallah , James Finke , Jin Sub Kim , Paul G. Pavicic Jr., Marcelo Lamenza , Donna Company , Andrew J. Stephenson , Steven Campbell , Georges-Pascal Haber , Byron H Lee , Omar Y. Mian , Timothy D. Gilligan , Brian I. Rini , Jorge A. Garcia , Petros Grivas , Moshe Chaim Ornstein

Organizations

Cleveland Clinic, Cleveland, OH, Cleveland Clinic Lerner Research Institute, Cleveland, OH, Cleveland Clinic Foundation, Cleveland, OH, Memorial Hospital of Rhode Island, Pawtucket, RI, Cleveland Clinic Taussig Cancer Insitute, Cleveland, OH, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Cleveland Clinic Glickman Urology and Kidney Institute, Cleveland, OH, Cleveland Clinic, Dept. of Radiation Oncology, Dept. of Translational Hematology Oncology Research, Cleveland, OH, University of Washington/Seattle Cancer Care Alliance, Seattle, WA

Research Funding

Other

Background: MDSC have been linked to the chronic inflammatory microenvironment of tumor cells and pathologic outcomes in UC patients (pts) undergoing cystectomy. NLR is an established inflammatory biomarker with prognostic properties in mUC. We hypothesized that MDSCs correlate with NLR and OS in mUC. Methods: MDSCs were measured in blood samples from mUC patients by fresh unfractionated whole blood (WB) and peripheral blood mononuclear cells (PBMC). MDSCs were identified by flow cytometry in WB and defined as LinloCD33+/HLADR- (Total MDSC). MDSC subsets were defined as polymorphonuclear (PMN-MDSC: CD15+/CD14-), monocytic (M-MDSC: CD15-/CD14+), and uncommitted (UC-MDSC: CD15-/CD14-). MDSC populations were presented as % of live nucleated blood cells from PB and absolute numbers from WB. Spearman’s correlation assessed correlations between MDSC & NLR. Kaplan Meier curves and log rank test estimated OS from the time of MDSC collection to last follow up or date of death. Results: Of 79 pts, 77% were men and 42% were never smokers with a median age of 69 (31-83). Overall, 71% had pure UC and 81% had lower tract UC. Prior therapies include intravesical therapy (22%), neoadjuvant chemotherapy (31%), and cystectomy/nephroureterectomy (61%). Median follow up was 12 months (range: 0.6-36.5). PMN-MDSC was the predominant subset in WB and PBMC. There was significant correlation between individual MDSC subsets in WB and PBMC (p≤0.001). Negative correlation was noted between NLR and WB UC-MDSC:PMN-MDSC ratios (rho = -0.27, p = 0.03), as well as NLR and PB UC-MDSC:PMN-MDSC (rho = -0.28, p = 0.02). Median survival was 17.7 months (95% CI: 11.0-NA months). Overall 1-yr and 3-yr survival were 0.60 (95% CI: 0.49-0.73) and 0.15 (95% CI: 0.03-0.67), respectively. Higher WB UC-MDSC levels were associated with shorter OS (HR 2.85, 95% CI: 1.43-5.65, p = 0.003). Conclusions: Specific MDSC subsets correlate with NLR. Higher WB UC-MDSC levels have negative prognostic roles for OS. Given the feasibility of serial blood draws, dynamic assessment of MDSC over time and further validation with longer follow up are needed.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers

Sub Track

Urothelial Carcinoma

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 436)

DOI

10.1200/JCO.2019.37.7_suppl.436

Abstract #

436

Poster Bd #

J7

Abstract Disclosures

Similar Abstracts

First Author: MInoru Kato

Abstract

2023 ASCO Annual Meeting

Systemic inflammation markers ratio in heavily pretreated NSCLC patients treated with nivolumab.

First Author: Lela Bitar